Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study.
Clin Cancer Res
; 29(22): 4698, 2023 Nov 14.
Article
in En
| MEDLINE
| ID: mdl-37960920
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Clin Cancer Res
Journal subject:
NEOPLASIAS
Year:
2023
Type:
Article